School of Laboratory Medicine and Life Sciences, Wenzhou Medical University; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention.
Faculty of Health Sciences, University of Macau; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences.
J Vis Exp. 2021 Mar 10(169). doi: 10.3791/61462.
The major histocompatibility complex (MHC) plays a pivotal role in antigen peptide presentation and T cell immune responses against infectious disease and tumor development. The hybrid MHC I complexed with heterologous β2-microglobulin (β2m) substitution from different species can be stabilized in vitro. This is a feasible means to study MHC I of mammals, when the homologous β2m is not available. Meanwhile, it is indicated that mammalian β2m substitution does not significantly affect peptide presentation. However, there is limited summarization regarding the methodology and the technology for the hybrid MHC I complexed with heterologous β2-microglobulin (β2m). Herein, methods to evaluate the feasibility of heterologous β2m substitution in MHC I study are presented. These methods include preparation of expression constructs; purification of inclusion bodies and refolding of the MHC complex; determination of protein thermostability; crystal screening and structure determination. This study provides a recommendation for understanding function and structure of MHC I, and is also significant for T cell response evaluation during infectious disease and tumor immunotherapy.
主要组织相容性复合体(MHC)在抗原肽呈递和 T 细胞免疫反应中起着关键作用,可对抗感染性疾病和肿瘤的发生发展。来自不同物种的异源β2-微球蛋白(β2m)替代的混合 MHC I 复合物可以在体外稳定。当同源β2m 不可用时,这是研究哺乳动物 MHC I 的一种可行方法。同时,有研究表明,哺乳动物β2m 的替代不会显著影响肽呈递。然而,关于与异源β2-微球蛋白(β2m)复合的混合 MHC I 的方法和技术还没有得到充分总结。本文介绍了评估 MHC I 研究中异源β2m 替代可行性的方法,包括表达构建体的制备、包涵体的纯化和 MHC 复合物的复性、蛋白热稳定性的测定、晶体筛选和结构测定。本研究为理解 MHC I 的功能和结构提供了建议,对于评估感染性疾病和肿瘤免疫治疗期间 T 细胞反应也具有重要意义。